VivoSeq
Other

Ovarian Reserve

35

Pipeline Programs↗

9

Active Trials↗

14

Companies Involved↗

Ovarian Reserve is a moderately active landscape with 35 programs across 14 companies. The most active players are Bayer, Eli Lilly, Neurim Pharmaceuticals Ltd.. 8 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

79/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3N

Neurim Pharmaceuticals Ltd.

1 program

Phase 3I

Inflabloc Pharmaceuticals

1 program

Phase 3AbbVie logo

AbbVie

1 program

ApprovedEMD Serono logo

EMD Serono

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

46 of 48 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody12%Vaccine12%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 100% of 51 pipeline programs.

Analysis

Trial Status

39

clinical trials

Unknown status16 · 41%
Completed11 · 28%
Recruiting4 · 10%
Active, not recruiting3 · 8%
Terminated2 · 5%
Not yet recruiting2 · 5%
Other1 · 3%

Clinical Trials

Trial Activity

39 trials

Open, Non-comparative Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Plasma Rich in Growth Factors (PRGF) in Patients With Low Ovarian Reserve
Recruiting·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·N/A·NCT06975683·50 enrolled
Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET
Recruiting·SShandong University of Traditional Chinese Medicine·Phase 4·NCT04872660·800 enrolled
hCG Priming in Women With Diminished Ovarian Reserve
Recruiting·—·Phase 3·NCT07108621·80 enrolled
Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment
Recruiting·PPeking Union Medical College Hospital·Phase 3·NCT07376824·90 enrolled
Ovarian Reserve Testing in Female Young Adult Cancer Survivors
Active, not recruiting·UUniversity of California, San Diego·N/A·NCT01421095·34 enrolled
Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients
Active, not recruiting·PPeking University People's Hospital·N/A·NCT02430103·349 enrolled
Melatonin Therapy for Improving ICSI Outcomes in Women With Diminished Ovarian Reserve
Active, not recruiting·—·Phase 2·NCT07318974·64 enrolled
Testing Herbal Pretreatment For IVF Success In Women With Low Ovarian Reserve
Not yet recruiting·PPeking Union Medical College Hospital·Phase 3·NCT07347340·348 enrolled
of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve
Not yet recruiting·—·Phase 3·NCT06405204·200 enrolled
The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy
Completed·—·N/A·NCT02714998·131 enrolled
Electroacupuncture for Diminished Ovarian Reserve
Completed·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·Phase 1·NCT02229604·57 enrolled
hCG Priming in Women With Low Ovarian Reserve
Completed·—·Phase 4·NCT04643925·20 enrolled
Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study
Completed·WWake Forest University Health Sciences·Phase 4·NCT01921166·23 enrolled
Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve
Completed·LLaboratorios Andromaco S.A.·Phase 1·NCT02268032·94 enrolled
Human Chorionic Gonadotropin (hCG) Test: A Novel Method to Evaluate the Ovarian Reserve
Completed·HHadassah Medical Organization·N/A·NCT00646568·60 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)